Pretreatment with SDG prevents iron induced decrease in H9c2 cell size. by Stephanie Puukila (568109)

Predictive values of IC₅₀ in mM (FFAs) for vanadium compounds and <i>in vivo</i> observations IC₅₀ in mM (FFAs) and decreasing blood glucose level. by Elena V. Fedorova (603922)

“…<p>Predictive values of IC₅₀ in mM (FFAs) for vanadium compounds and <i>in vivo</i> observations IC₅₀ in mM (FFAs) and decreasing blood glucose level.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”

Decrease in GABA in APP mice. by Ksenia V. Kastanenka (3692380)

Predicted cylindrical cavity pressure as a function of saturation for two clay contents (16 and 50%) and for a range of cavity radii (1 to 5 mm). by Siul Ruiz (757454)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Calcium release from <i>S</i>. <i>mutans</i> at decreasing pHs. by Tarcísio Jorge Leitão (4811379)

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Corticosterone treatment decreases MMP-2 promoter activity. by Eric A. Shikatani (131260)

“…MMP-2 mRNA levels were decreased with corticosterone treatment (A) (p = 0.006, n = 5). …”

ROS and superoxide decrease in the dormant form of mycobacteria. by Amar Yeware (7115063)